Clinical Pharmacokinetics

, Volume 29, Issue 1, pp 1–5 | Cite as

Novel Delivery of Antiarrhythmic Agents

  • Vinod Labhasetwar
  • Robert J. Levy
Leading Article


Conventional antiarrhythmia therapy by oral or intravenous routes of administration is often ineffective and results in drug-associated complications and toxicity. In addition, poor bioavailability and a high first-pass effect limit therapeutic applications of several investigational antiarrhythmic compounds, which are otherwise more potent and less toxic than available agents. The regional nature of the several cardiac diseases, such as ischaemia, restenosis or heart valve calcification, may require a high concentration of drug at the location of the disease, which by conventional routes may not be attainable due to systemic toxicity of the drug.

Localised cardiac delivery of antiarrhythmic agents, based on drug-polymer implants, may have several advantages, including enhanced drug effects and reduced systemic drug toxicity. Computer-assisted automated feedback systems may further enhance the usefulness of this therapy in the clinical setting.

Before clinical application of this method of drug delivery further study will be required, but it is hypothesised that pharmacokinetic variability for drugs delivered in this manner will be reduced and therefore efficacy and toxicity will be more predictable.


Sotalol Antiarrhythmic Agent Dofetilide Ibutilide Amidon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brugada G. ‘Torsade de Pointes’. PACE 1988; 11: 2246–8PubMedCrossRefGoogle Scholar
  2. 2.
    Lee KS, Lee EW. Membrane activities of Class III antiarrhythmic compounds: a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. Eur J Pharmacol 1993; 234: 43–53PubMedCrossRefGoogle Scholar
  3. 3.
    Lee KS. Ibutilide, a new compound with potent Class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992; 262: 99–108PubMedGoogle Scholar
  4. 4.
    Labhasetwar V, Levy RJ. Polymer systems for cardiovascular drug delivery. Polymer News 1992; 17: 336–42Google Scholar
  5. 5.
    Labhasetwar V, Kadish A, Underwood T, et al. The efficacy of controlled release d-sotalol-polyurethane epicardial implants for ventricular arrhythmias due to acute ischemia in dogs. J Control Release 1993; 23: 75–86CrossRefGoogle Scholar
  6. 6.
    Labhasetwar V, Underwood T, Gallagher M, et al. Sotalol controlled-release systems for arrhythmias: in vitro characterization, in vivo drug disposition, and electrophysiologic effects. J Pharm Sci 1994; 83: 157–64CrossRefGoogle Scholar
  7. 7.
    Labhasetwar V, Underwood T, Gallagher M, et al. Epicardial controlled release ibutilide: effects on defibrillation threshold and electrophysiologic parameters. J Cardiovasc Pharmacol 1994; 24: 826–40PubMedCrossRefGoogle Scholar
  8. 8.
    Siden R, Kadish A, Flowers W, et al. Epicardial controlled-release verapamil prevents ventricular tachycardia episodes induced by acute ischemia in a canine model. J Cardiovasc Pharmacol 1992; 19: 798–809PubMedGoogle Scholar
  9. 9.
    Sintov A, Scott W, Dick M, et al. Cardiac controlled release for arrhythmia therapy: lidocaine-polyurethane matrix studies. J Control Release 1988; 8: 157–65CrossRefGoogle Scholar
  10. 10.
    Sintov A, Scott WA, Gallagher KP, et al. Conversion of ouabain-induced ventricular tachycardia in dogs with epicardial lidocaine: pharmacodynamics and functional effects. Pharm Res 1990; 7: 28–33PubMedCrossRefGoogle Scholar
  11. 11.
    Sintov A, Scott WA, Siden R, et al. Efficacy of epicardial controlled-release lidocaine for ventricular tachycardia induced by rapid ventricular pacing in dogs. J Cardiovasc Pharmacol 1990; 16: 812–7PubMedCrossRefGoogle Scholar
  12. 12.
    Siden R, Flowers W, Levy R. Epicardial propranolol administration for ventricular arrhythmias in dogs: matrix formulation and characterization. Biomaterials 1992; 13: 763–70CrossRefGoogle Scholar
  13. 13.
    Schwendeman SP, Amidon GL, Labhasetwar V, et al. Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes, II: influence of cation-exchanger content on membrane resistance and characteristic times. J Pharm Sci 1994; 83: 1482–93PubMedCrossRefGoogle Scholar
  14. 14.
    Schwendeman SP, Amidon GL, Meyerhoff ME, et al. Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes: membrane preparation and influence of resin cross-linkage. Macromolecules 1992; 25: 2531–40CrossRefGoogle Scholar
  15. 15.
    Schwendeman SP, Amidon GL, Levy RJ. Determinants of the modulated release of antiarrhythmic drugs by iontophoresis through polymer membranes. Macromolecules 1993; 26: 2264–72CrossRefGoogle Scholar
  16. 16.
    Labhasetwar V, Underwood T, Schwendeman S, et al. Iontophoresis for modulation of cardiac drug delivery. Proc Natl Acad Sci USA 1995; 92: 2612–6PubMedCrossRefGoogle Scholar
  17. 17.
    Avitall B, Hare J, Zander G, et al. Iontophoretic transmyocardial drug delivery: a novel approach to antiarrhythmic drug therapy. Circulation 1992; 85: 1582–93PubMedCrossRefGoogle Scholar
  18. 18.
    Fernandez-Ortiz A, Meyer BJ, Mailhac A, et al. A new approach for local intravascular drug delivery: iontophoretic balloon. Circulation 1994; 89: 1518–22PubMedCrossRefGoogle Scholar
  19. 19.
    Schwendeman S, Labhasetwar V, Levy R. Model features of a cardiac iontophoretic drug delivery implant. Pharm Res 1995; 12: 790–5PubMedCrossRefGoogle Scholar
  20. 20.
    Winkle R, Mead R, Ruder M, et al. Long-term outcome with the automatic implantable cardioverter defibrillator. J Am Coll Cardiol 1989; 13: 1353–61PubMedCrossRefGoogle Scholar
  21. 21.
    Gene therapy for cardiovascular disease [editorial]. Br Heart J 1994; 72: 309–12Google Scholar
  22. 22.
    Takeshita S, Zheng L, Asahara T, et al. In vivo evidence of enhanced angiogenesis following direct arterial gene transfer of the plasmid encoding vascular endothelial growth factor [abstract]. Circulation 1993; 88: 1–476Google Scholar
  23. 23.
    Simons M, Edelman E, DeKeyser J-L, et al. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67–70PubMedCrossRefGoogle Scholar
  24. 24.
    Villa A, Guzman L, Poptic E, et al. The effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res 1995; 76(4): 505–13PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Vinod Labhasetwar
    • 1
  • Robert J. Levy
    • 1
  1. 1.Division of Pediatrie CardiologyUniversity of Michigan Medical CenterAnn ArborUSA

Personalised recommendations